Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 107


Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.

Dabydeen SA, Kang K, Díaz-Cruz ES, Alamri A, Axelrod ML, Bouker KB, Al-Kharboosh R, Clarke R, Hennighausen L, Furth PA.

Carcinogenesis. 2015 Jan;36(1):122-32. doi: 10.1093/carcin/bgu237. Epub 2014 Nov 23.


The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.

Bae WK, Yoo KH, Lee JS, Kim Y, Chung IJ, Park MH, Yoon JH, Furth PA, Hennighausen L.

Mol Carcinog. 2015 Oct;54(10):1172-80. doi: 10.1002/mc.22188. Epub 2014 Jul 7.


Cardiomyocyte-specific Estrogen Receptor Alpha Increases Angiogenesis, Lymphangiogenesis and Reduces Fibrosis in the Female Mouse Heart Post-Myocardial Infarction.

Mahmoodzadeh S, Leber J, Zhang X, Jaisser F, Messaoudi S, Morano I, Furth PA, Dworatzek E, Regitz-Zagrosek V.

J Cell Sci Ther. 2014 Jan 30;5(1):153.


Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation.

Cabrera MC, Tilahun E, Nakles R, Diaz-Cruz ES, Charabaty A, Suy S, Jackson P, Ley L, Slack R, Jha R, Collins SP, Haddad N, Kallakury BV, Schroeder T, Pishvaian MJ, Furth PA.

Front Oncol. 2014 May 9;4:102. doi: 10.3389/fonc.2014.00102. eCollection 2014.


Oestrogen receptor-alpha regulates non-canonical Hedgehog-signalling in the mammary gland.

Okolowsky N, Furth PA, Hamel PA.

Dev Biol. 2014 Jul 15;391(2):219-29. doi: 10.1016/j.ydbio.2014.04.007. Epub 2014 Apr 21.


Trp63 is regulated by STAT5 in mammary tissue and subject to differentiation in cancer.

Assefnia S, Kang K, Groeneveld S, Yamaji D, Dabydeen S, Alamri A, Liu X, Hennighausen L, Furth PA.

Endocr Relat Cancer. 2014 May 6;21(3):443-57. doi: 10.1530/ERC-14-0032. Print 2014 Jun.


Genetically engineered ERα-positive breast cancer mouse models.

Dabydeen SA, Furth PA.

Endocr Relat Cancer. 2014 May 6;21(3):R195-208. doi: 10.1530/ERC-13-0512. Print 2014 Jun. Review.


The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ.

Ory V, Tassi E, Cavalli LR, Sharif GM, Saenz F, Baker T, Schmidt MO, Mueller SC, Furth PA, Wellstein A, Riegel AT.

Oncogene. 2014 Jun 5;33(23):3033-42. doi: 10.1038/onc.2013.263. Epub 2013 Jul 15.


STAT signaling in different breast cancer sub-types.

Furth PA.

Mol Cell Endocrinol. 2014 Jan 25;382(1):612-5. doi: 10.1016/j.mce.2013.03.023. Epub 2013 Apr 3. Review.


Time-lapse imaging of primary preneoplastic mammary epithelial cells derived from genetically engineered mouse models of breast cancer.

Nakles RE, Millman SL, Cabrera MC, Johnson P, Mueller S, Hoppe PS, Schroeder T, Furth PA.

J Vis Exp. 2013 Feb 8;(72). pii: 50198. doi: 10.3791/50198.


Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations.

Furth PA.

Ann N Y Acad Sci. 2012 Oct;1271:1-9. doi: 10.1111/j.1749-6632.2012.06736.x. Review.


Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered Mice.

Miermont AM, Cabrera MC, Frech SM, Nakles RE, Diaz-Cruz ES, Shiffert MT, Furth PA.

Anat Physiol. 2012 Jun 25;Suppl 12. pii: 001.


The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.

Cabrera MC, Díaz-Cruz ES, Kallakury BV, Pishvaian MJ, Grubbs CJ, Muccio DD, Furth PA.

Cancer Prev Res (Phila). 2012 Jun;5(6):810-21. doi: 10.1158/1940-6207.CAPR-11-0532-T. Epub 2012 Apr 16.


Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer.

Furth PA, Nakles RE, Millman S, Diaz-Cruz ES, Cabrera MC.

Breast Cancer Res. 2011 Oct 12;13(5):220. doi: 10.1186/bcr2921. Review.


Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer.

Díaz-Cruz ES, Sugimoto Y, Gallicano GI, Brueggemeier RW, Furth PA.

Cancer Res. 2011 Aug 15;71(16):5477-87. doi: 10.1158/0008-5472.CAN-10-4652.


Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Furth PA, Cabrera MC, Díaz-Cruz ES, Millman S, Nakles RE.

Ann N Y Acad Sci. 2011 Jul;1229:147-55. doi: 10.1111/j.1749-6632.2011.06086.x. Review.


BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.

Diaz-Cruz ES, Cabrera MC, Nakles R, Rutstein BH, Furth PA.

Breast Dis. 2010;32(1-2):85-97. doi: 10.3233/BD-2010-0308. Review.


Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.

Nakles RE, Shiffert MT, Díaz-Cruz ES, Cabrera MC, Alotaiby M, Miermont AM, Riegel AT, Furth PA.

Mol Endocrinol. 2011 Apr;25(4):549-63. doi: 10.1210/me.2010-0114. Epub 2011 Feb 3.


Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia.

Díaz-Cruz ES, Furth PA.

Cancer Res. 2010 May 15;70(10):3965-74. doi: 10.1158/0008-5472.CAN-09-3450.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk